Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AGPAT2 | O15120 | 1/20 | 0.39 |
| ▸ | FCGR3B | O75015 | 1/20 | 0.39 |
| ▸ | FCGR1A | P12314 | 1/20 | 0.39 |
| ▸ | FCGR2A | P12318 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | CDK1 | P06493 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7169031 | 0.92 | MEN1 (0.49) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL7017813 | 0.87 | MEN1 (0.49) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL1625684 | 0.86 | AGPAT2 (0.42) | MEN1KMT2ACDC7ALKALDH1A1 | |
| SCHEMBL3950718 | 0.83 | KMT2A (0.50) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL1625442 | 0.82 | MEN1 (0.50) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL1625505 | 0.81 | MEN1 (0.49) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL1626147 | 0.81 | MEN1 (0.49) | MEN1KMT2ARAB9ANPC1ALDH1A1 | |
| SCHEMBL1623514 | 0.80 | MEN1 (0.41) | MEN1KMT2ACDC7ALKRAB9A | |
| SCHEMBL1626044 | 0.79 | CDC7 (0.40) | MEN1KMT2ACDC7ALKALDH1A1 | |
| SCHEMBL1624553 | 0.79 | PDE4B (0.40) | MEN1KMT2ARAB9ANPC1AGPAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106745722-A | A kind of mobile tunnel type anaerobic pond support meanss and its method of work | 徐州工程学院 | 2017-05-31 | — | — | CN | claimed |
| CN-106745722-B | Mobile tunnel type anaerobic tank supporting device and working method thereof | 徐州腾睿智能装备有限公司 | 2020-09-15 | — | — | CN | disclosed |
| CN-106745722-A | A kind of mobile tunnel type anaerobic pond support meanss and its method of work | 徐州工程学院 | 2017-05-31 | — | — | CN | disclosed |
| EP-1666480-B1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | RAQUALIA PHARMA INC (JP) | 2014-10-01 | — | — | EP | disclosed |
| US-7960407-B2 | Crystal forms of an imidazole derivative | REQUALIA PHARMA INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| CN-101137656-B | Crystal forms of imidazole derivatives | PFIZER JAPAN INC | 2010-12-22 | — | — | CN | disclosed |
| EP-1861400-B1 | CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE | RAQUALIA PHARMA INC (JP) | 2010-05-26 | — | — | EP | disclosed |
| WO-2005102389-A9 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2009-04-30 | — | — | WO | disclosed |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PFIZER, INC. | 2009-02-05 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| CN-1476448-A | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ������ҩ������˾ | 2004-02-18 | — | — | CN | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| WO-2003086371-A2 | USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES | PFIZER JAPAN INC. (JP) | 2003-10-23 | — | — | WO | disclosed |
| EP-1326864-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| EP-1326606-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2003-07-16 | — | — | EP | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
| WO-2002032422-A2 | EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
| WO-2002032900-A2 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | MEN1 3912/4885KMT2A 2917/4885CDC7 4230/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | MEN1 4475/4885KMT2A 4355/4885CDC7 4334/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | MEN1 4826/4885KMT2A 3764/4885CDC7 4194/4885 |
| US-20090036495-A1 | Combinations Comprising Alpha-2-Delta Ligands and Ep4 Receptor Antagonists | PTGER4, PTGER2, OPRL1 | MEN1 4563/4885KMT2A 2227/4885CDC7 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.